Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.42 |
| ▸ | PGR | P06401 | 3/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27354573 | 0.82 | ALDH1A1 (0.45) | MAPTKDM4EHSD17B10ALDH1A1POLB | |
| SCHEMBL6087830 | 0.78 | MAPT (0.52) | MAPTKDM4EHSD17B10ALDH1A1POLB | |
| SCHEMBL8065215 | 0.76 | CYP1A2 (0.50) | MAPTKDM4EHSD17B10ALDH1A1NPSR1 | |
| SCHEMBL30696827 | 0.76 | MAOA (0.43) | MAPTKDM4EHSD17B10GAAMAOA | |
| SCHEMBL26994676 | 0.75 | MAOA (0.59) | MAPTKDM4EALDH1A1POLBNPSR1 | |
| SCHEMBL27354574 | 0.74 | MAPT (0.43) | MAPTKDM4EHSD17B10ALDH1A1GAA | |
| SCHEMBL30696747 | 0.74 | MAPT (0.43) | MAPTKDM4EHSD17B10ALDH1A1GAA | |
| SCHEMBL6086189 | 0.70 | MAPT (0.71) | MAPTKDM4EHSD17B10ALDH1A1POLB | |
| SCHEMBL5558567 | 0.70 | MAPT (0.61) | MAPTKDM4EHSD17B10ALDH1A1POLB | |
| SCHEMBL29606212 | 0.69 | MAPT (0.66) | MAPTKDM4EHSD17B10ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4543439-A2 | NRF2 PROTEIN DEGRADERS | Ganymede Oncology, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119730847-A | NRF2 protein degradation agent | 盖尼米德肿瘤学股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | MAPT 3815/4885KDM4E 1719/4885HSD17B10 346/4885 |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | MAPT 1641/4885KDM4E 643/4885HSD17B10 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.